We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Journal Scan / Research · November 16, 2022

Nivolumab Plus Ipilimumab Plus Cabozantinib Triplet Combination for Patients With Previously Untreated Advanced RCC

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
Eur. J. Cancer 2022 Dec 01;177(xx)63-71, AB Apolo, T Powles, B Escudier, M Burotto, J Zhang, B Simsek, C Scheffold, RJ Motzer, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading